We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Preventing Type II Diabetes Requires Putting the Brakes on Zinc Transport Protein

By LabMedica International staff writers
Posted on 29 Dec 2016
The enhanced activity of a zinc transport protein encoded by a fairly common gene variant has been linked to heightened risk of developing type II diabetes.

Zinc is a critical element for insulin storage in the secretory granules of pancreatic beta cells. More...
The islet-specific zinc transporter ZnT8 mediates granular sequestration of zinc ions. A genetic variant of human ZnT8 arising from a single nonsynonymous nucleotide change in the SLC30A8 (solute carrier family 30 member 8) gene contributes to increased susceptibility to type II diabetes, but it has remained unclear how the high-risk variant (R325), which is also a higher-frequency allele, is correlated with zinc transport activity.

Previous genomics studies have shown that variants of SLC30A8 were closely related to risk of developing type II diabetes. Individuals with the more common R325 version of the gene had a 12% greater likelihood of developing the disease than did those with the less common W325 form. Individuals with a very rare, inactive form of the gene had very low risk of developing type II diabetes.

In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) compared the activity of R325 with that of the low-risk W325 ZnT8 variant. They reported in the November 8, 2016, online edition of the Journal of Biological Chemistry that the R325 variant was some 57% more active than the W325 form following induced expression in HEK293 cells.

Over a broad range of permissive lipid compositions, the R325 variant consistently exhibited accelerated zinc transport kinetics versus the W form. In agreement with the human genetic finding that rare loss-of-function (LOF) mutations in ZnT8 were associated with reduced type II diabetes risk, these results suggested that the common high-risk R325 variant was hyperactive.

"Given that type II diabetes is a growing global epidemic, it has long seemed that a drug targeting the protein SLC30A8 makes, namely ZnT8 or zinc transporter 8, would potentially have a huge impact," said senior author Dr. Dax Fu, associate professor of physiology at Johns Hopkins University. "The problem was that studies on ZnT8 had not clarified whether the protein needed to be souped up or slowed down to reduce risk. In this case, breaking the "speed limit" brings disease risk."

Related Links:
Johns Hopkins University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.